Camrelizumab Combined With or Without Apatinib and SOX of Neoadjuvant Treatment for Gastric Cancer

Sponsor
Ruijin Hospital
Study ID
NCT06693128
Phase
PHASE2
Status
Active Not Recruiting

Conditions

  • Gastric and Gastroesophageal Junction (GEJ) Adenocarcinoma

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Camrelizumab — DRUG
    Camrelizumab 200mg
  • Apatinib — DRUG
    Apatinib 250mg
  • S-1, Oxaliplatin — DRUG
    S-1, Oxaliplatin, q3w

Study Details

This study is a multicenter, randomized, uncontrolled clinical trial to evaluate the efficacy and safety of camrelizumab combined with or without apatinib and SOX of neoadjuvant treatment for resectable locally advanced gastric or gastroesophageal junction adenocarcinoma.

Key Dates

Start date
Nov 21, 2024
Status verified
Jan 2026
Primary completion
May 30, 2026
Completion
Dec 31, 2027

Study Design

Enrollment
80 participants (estimated)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Experimental: Camrelizumab and Apatinib and S-1 and Oxaliplatin
  • Experimental: Camrelizumab and S-1 and Oxaliplatin

Primary Outcome Measure

Pathological Complete Response (pCR) [ Time Frame: Up to 6 weeks after completion of 3 cycles (each cycle is 21 days) of neoadjuvant treatment ]

Related Studies